comparemela.com

Latest Breaking News On - Corvus pharmaceuticals company profile - Page 1 : comparemela.com

Insider Buying: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Buys $34,600.00 in Stock

Insider Buying: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Buys $34,600.00 in Stock
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

William-benton-jones
Securities-exchange-commission
Corvus-pharmaceuticals-stock
Corvus-pharmaceuticals-company-profile
Corvus-pharmaceuticals-inc
Hedge-funds-weigh-in-on-corvus-pharmaceuticals
Nasdaq
Cantor-fitzgerald
Corvus-pharmaceuticals
News-ratings-for-corvus-pharmaceuticals-daily
Get-free-report
Free-report

Corvus Pharmaceuticals (CRVS) Set to Announce Earnings on Monday

Corvus Pharmaceuticals (CRVS) Set to Announce Earnings on Monday
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

News-ratings-for-corvus-pharmaceuticals-daily
Corvus-pharmaceuticals-company-profile
Earnings-history-for-corvus-pharmaceuticals
Corvus-pharmaceuticals
Cantor-fitzgerald
Corvus-pharmaceuticals-inc
Corvus-pharmaceuticals-stock-performance
Get-free-report
Corvus-pharmaceuticals-daily

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Update

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,490,000 shares, an increase of 17.3% from the February 29th total of 1,270,000 shares. Based on an average daily trading volume, of 218,100 […]

Corvus-pharmaceuticals-stock-performance
Tucker-asset-management
Corvus-pharmaceuticals-inc
Cantor-fitzgerald
Nasdaq
Renaissance-technologies
News-ratings-for-corvus-pharmaceuticals-daily
Corvus-pharmaceuticals-company-profile
Corvus-pharmaceuticals
Institutional-trading-of-corvus-pharmaceuticals
Tower-research-capital

Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Nasdaq
Vanguard-group-inc
Tucker-asset-management
Corvus-pharmaceuticals-company-profile
Corvus-pharmaceuticals-trading
Corvus-pharmaceuticals
Corvus-pharmaceuticals-inc
American-century-companies-inc
News-ratings-for-corvus-pharmaceuticals-daily

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Above 50-Day Moving Average of $1.43

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $1.43 and traded as high as $1.54. Corvus Pharmaceuticals shares last traded at $1.51, with a volume of 105,012 shares traded. Analyst Ratings Changes A number […]

Nasdaq
Corvus-pharmaceuticals
Charles-schwab-investment-management-inc
Cantor-fitzgerald
Tower-research-capital
Institutional-trading-of-corvus-pharmaceuticals
Corvus-pharmaceuticals-company-profile
York-mellon-corp
Corvus-pharmaceuticals-price-performance
Virtu-financial
Tucker-asset-management

vimarsana © 2020. All Rights Reserved.